



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	Appl. Serial Number	10/049,634
	Filing Date	February 25, 2002
	First Named Inventor	Viktor Magdolen
	Group Art Unit	1621
	Examiner Name	S. KUMAR
	Attorney Docket Number	2923.475
Title: Selective Inhibitors of the Urokinase Plasminogen Activator		

DECLARATION UNDER 37 C.F.R. §1.132

Commissioner for Patents
Alexandria, VA

Dear Sir:

The undersigned solemnly declares that:

1. I am one of the Inventors of the above-referenced patent application.
2. I have read and understood the Office Action dated April 15, 2004, issued in connection with the present application and U.S. Patent No. 6,534,546 to Honda et al.
3. I am aware that the claims 15-16, 18, 23-24, 28-41 and 43-45 of the above application have been rejected in the Office Action dated April 15, 2004 as obvious in view of U.S. Patent No. 6,534,546 to Honda et al.
5. I am also aware that independent claims 15 specifies that the substituents -CH₂X¹ and -NHC(NH)NH₂ of formula (I) as depicted in claim 15 are arranged in a para position to each other.

6. Our laboratory measured inhibition constants (K_i) of compounds of formula (I) as shown in claim 15 in which the substituents $-\text{CH}_2\text{X}^1$ and $-\text{NHC}(\text{NH})\text{NH}_2$ of formula (I) are arranged in para- and in meta- position.

7. In particular, K_i values for two meta-substituted compounds that, apart from their being meta-substituted instead of para-substituted, correspond to the compounds disclosed in the application as ST242 and ST293 (see Table 1) were measured.

8. The K_i values of these meta-substituted compounds for uPA exceeded 1000.

9. These high K_i values indicate a low affinity of these compounds for uPA.

10. Thus, these meta-substituted compounds were considered to have tested negative for having inhibitory action on uPA.

11. In contrast, as shown in Table 1 of the specification, para-substituted compounds ST242 and ST293 had K_i values for uPA of 36 and 2.4, respectively (Table 1, page 16, last listed compound and, page 17, second listed compound).

12. Based on the experiments described above, I have formed the opinion that para-substituted compounds as claimed in Claim 15 and claims dependent thereon display unexpected inhibitory results over the compounds disclosed by Honda.

13. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor:

Oref Willich
[Signature]

Date: 5/31/04